CARDIFF ONCOLOGY, INC. Costs and Expenses
CARDIFF ONCOLOGY, INC. (CRDF) reported Costs and Expenses of $4.00 million for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2014-11-06
- CARDIFF ONCOLOGY, INC. costs and expenses for the quarter ending 2014-09-30 was $4.00M, a 28.06% increase year-over-year.
- CARDIFF ONCOLOGY, INC. costs and expenses for the quarter ending 2014-06-30 was $3.30M, a 36.07% increase year-over-year.
- CARDIFF ONCOLOGY, INC. costs and expenses for the quarter ending 2014-03-31 was $3.37M, a 34.34% increase year-over-year.
- CARDIFF ONCOLOGY, INC. costs and expenses for the quarter ending 2013-12-31 was $2.90M, a 81.29% increase year-over-year.
- CARDIFF ONCOLOGY, INC. costs and expenses for fiscal 2013 was $10.95M, a 106.62% increase from fiscal 2012.
- CARDIFF ONCOLOGY, INC. costs and expenses for fiscal 2012 was $5.30M, a 63.84% increase from fiscal 2011.
- CARDIFF ONCOLOGY, INC. costs and expenses for fiscal 2011 was $3.23M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month | Costs and Expenses 152 month | Costs and Expenses 155 month | Costs and Expenses 158 month | Costs and Expenses 161 month | Costs and Expenses 164 month | Costs and Expenses 167 month | Costs and Expenses 170 month | Costs and Expenses 173 month | Costs and Expenses 176 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | $4.00M 10-Q · filed 2014-11-06 | $7.29M derived: sum of 2 quarters · filed 2014-11-06 | $10.67M 10-Q · filed 2014-11-06 | $13.56M derived: sum of 4 quarters · filed 2014-11-06 | ||||||||||
| 2014-06-30 | $3.30M 10-Q · filed 2014-08-07 | $6.67M 10-Q · filed 2014-08-07 | $9.56M derived: sum of 3 quarters · filed 2014-08-07 | $12.69M derived: sum of 4 quarters · filed 2014-11-06 | ||||||||||
| 2014-03-31 | $3.37M 10-Q · filed 2014-05-12 | $6.27M derived: sum of 2 quarters · filed 2014-05-12 | $9.39M derived: sum of 3 quarters · filed 2014-11-06 | $11.81M derived: sum of 4 quarters · filed 2014-11-06 | $60.36M 10-Q · filed 2014-05-12 | |||||||||
| 2013-12-31 | $2.90M 10-K · filed 2014-03-17 | $6.02M derived: sum of 2 quarters · filed 2014-11-06 | $8.44M derived: sum of 3 quarters · filed 2014-11-06 | $10.95M 10-K · filed 2014-03-17 | $56.99M 10-K · filed 2014-03-17 | |||||||||
| 2013-09-30 | $3.12M 10-Q · filed 2014-11-06 | $5.54M derived: sum of 2 quarters · filed 2014-11-06 | $8.05M 10-Q · filed 2014-11-06 | $9.65M derived: sum of 4 quarters · filed 2014-11-06 | $54.09M 10-Q · filed 2013-11-14 | |||||||||
| 2013-06-30 | $2.42M 10-Q · filed 2014-08-07 | $4.93M 10-Q · filed 2014-08-07 | $6.53M derived: sum of 3 quarters · filed 2014-08-07 | $7.78M derived: sum of 4 quarters · filed 2014-08-07 | $50.97M 10-Q · filed 2013-08-14 | |||||||||
| 2013-03-31 | $2.51M 10-Q · filed 2014-05-12 | $4.11M derived: sum of 2 quarters · filed 2014-05-12 | $5.36M derived: sum of 3 quarters · filed 2014-05-12 | $6.64M derived: sum of 4 quarters · filed 2014-05-12 | $48.55M 10-Q · filed 2013-05-14 | |||||||||
| 2012-12-31 | $1.60M 10-K · filed 2014-03-17 | $2.85M derived: sum of 2 quarters · filed 2014-03-17 | $4.13M derived: sum of 3 quarters · filed 2014-03-17 | $5.30M 10-K · filed 2014-03-17 | $46.04M 10-K · filed 2013-04-01 | |||||||||
| 2012-09-30 | $1.25M 10-K · filed 2014-03-17 | $1.25M 10-Q · filed 2012-11-14 | $2.54M derived: sum of 2 quarters · filed 2014-03-17 | $3.70M 10-Q · filed 2013-11-14 | $4.61M derived: sum of 4 quarters · filed 2014-03-17 | $44.44M 10-Q · filed 2012-11-14 | ||||||||
| 2012-06-30 | $1.29M 10-K · filed 2014-03-17 | $1.29M 10-Q · filed 2012-08-14 | $2.45M 10-Q · filed 2013-08-14 | $3.36M derived: sum of 3 quarters · filed 2014-03-17 | $4.15M derived: sum of 4 quarters · filed 2014-03-17 | $43.19M 10-Q · filed 2012-08-14 | ||||||||
| 2012-03-31 | $1.16M 10-K · filed 2014-03-17 | $1.16M 10-Q · filed 2012-05-15 | $2.07M derived: sum of 2 quarters · filed 2014-03-17 | $2.86M derived: sum of 3 quarters · filed 2014-03-17 | $3.59M derived: sum of 4 quarters · filed 2014-03-17 | $41.90M 10-Q · filed 2012-05-15 | ||||||||
| 2011-12-31 | $910.97K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $1.70M derived: sum of 2 quarters · filed 2014-03-17 | $2.43M derived: sum of 3 quarters · filed 2014-03-17 | $3.23M 10-K · filed 2014-03-17 | ||||||||||
| 2011-09-30 | $787.15K 10-Q · filed 2012-11-14 | $1.51M derived: sum of 2 quarters · filed 2012-11-14 | $2.32M 10-Q · filed 2012-11-14 | |||||||||||
| 2011-06-30 | $727.31K 10-Q · filed 2012-08-14 | $1.54M 10-Q · filed 2012-08-14 | ||||||||||||
| 2011-03-31 | $809.06K 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |